Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure

How to buy immatics biotechnologies GmbH stock | $3.84

Learn how to easily invest in immatics biotechnologies GmbH stock.

immatics biotechnologies GmbH is a business based in the US. immatics biotechnologies GmbH shares (IMTXW) are listed on the NASDAQ and all prices are listed in US Dollars. immatics biotechnologies GmbH employs 134 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in immatics biotechnologies GmbH

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – IMTXW – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

immatics biotechnologies GmbH stock price (NASDAQ: IMTXW)

Use our graph to track the performance of IMTXW stocks over time.

immatics biotechnologies GmbH shares at a glance

Information last updated 2021-08-09.
Latest market close$3.84
52-week range$2.26 - $5.55
50-day moving average $0.00
Wall St. target priceN/A
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy immatics biotechnologies GmbH shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
Vanguard Personal Advisor
Stocks, Options, Mutual funds, ETFs
$20 per year
Financial advice powered by relationships, not commissions.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
Deposit qualifying assets of $5,000+
A platform built for all kinds of traders and all styles of trading
Sofi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
$0 per year
Get a free stock valued up to $350
Open your Futu brokerage account via Moomoo
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy immatics biotechnologies GmbH stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

immatics biotechnologies GmbH price performance over time

Historical closes compared with the close of $3.84 from 2021-10-19

1 week (2021-10-13) -8.79%
1 month (2021-09-20) -8.13%
3 months (2021-07-20) 13.61%
6 months (2021-04-20) 11.63%
1 year (2020-10-20) 29.73%
2 years (2019-10-16) N/A
3 years (2018-10-16) N/A
5 years (2016-10-16) N/A

immatics biotechnologies GmbH financials

Gross profit TTM $0
Return on assets TTM 0%
Return on equity TTM 0%
Profit margin -156.4%
Book value N/A
Market capitalisation $673 million

TTM: trailing 12 months

Shorting immatics biotechnologies GmbH shares

There are currently 3,846 immatics biotechnologies GmbH shares held short by investors – that's known as immatics biotechnologies GmbH's "short interest". This figure is 48.3% down from 7,439 last month.

There are a few different ways that this level of interest in shorting immatics biotechnologies GmbH shares can be evaluated.

immatics biotechnologies GmbH's "short interest ratio" (SIR)

immatics biotechnologies GmbH's "short interest ratio" (SIR) is the quantity of immatics biotechnologies GmbH shares currently shorted divided by the average quantity of immatics biotechnologies GmbH shares traded daily (recently around inf billion). immatics biotechnologies GmbH's SIR currently stands at 0. In other words for every 100,000 immatics biotechnologies GmbH shares traded daily on the market, roughly 0 shares are currently held short.

However immatics biotechnologies GmbH's short interest can also be evaluated against the total number of immatics biotechnologies GmbH shares, or, against the total number of tradable immatics biotechnologies GmbH shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case immatics biotechnologies GmbH's short interest could be expressed as 0% of the outstanding shares (for every 100,000 immatics biotechnologies GmbH shares in existence, roughly 0 shares are currently held short) or 0% of the tradable shares (for every 100,000 tradable immatics biotechnologies GmbH shares, roughly 0 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against immatics biotechnologies GmbH.

Find out more about how you can short immatics biotechnologies GmbH stock.

immatics biotechnologies GmbH share dividends

We're not expecting immatics biotechnologies GmbH to pay a dividend over the next 12 months.

immatics biotechnologies GmbH overview

Immatics N. V. engages in the discovery of targets for cancer immunotherapies. It is developing targeted immunotherapies with focus on treating solid tumors through two distinct therapeutic modalities, such as Adoptive Cell Therapies and antibody-like TCR Bispecifics. Its pipeline comprises of eight therapeutic programs, of which four are in clinical trials and four are in preclinical development. The company is based in Tuebingen, Germany. .

immatics biotechnologies GmbH in the news

There are no recent company news

Frequently asked questions

How many people work for immatics biotechnologies GmbH?
Latest data suggests 134 work at immatics biotechnologies GmbH.
Where is immatics biotechnologies GmbH based?
immatics biotechnologies GmbH's address is: Paul-Ehrlich-Str. 15, Tuebingen, Germany, 72076

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site